Immunotherapy Cost in India

Best Immunotherapy Cost in India

Immunotherapy has changed what is possible in cancer treatment over the last decade. Checkpoint inhibitors — drugs that release the immune system’s natural ability to recognise and attack cancer cells — have produced durable responses in cancers that were previously considered largely untreatable: advanced melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, and others.

But immunotherapy is also among the most expensive categories of cancer treatment globally. In the United States, a single cycle of pembrolizumab (Keytruda) costs $10,000–$15,000. For patients who require 18–24 months of treatment, the cumulative cost can exceed $200,000. This is why an increasing number of international patients are exploring immunotherapy in India, where the same drugs — or clinically equivalent biosimilar versions — are available at 80–90% lower cost.

This guide gives you a clear picture of what immunotherapy costs in India, drug by drug, and what you need to understand to plan your treatment realistically.

Immunotherapy Cost in India: Drug-by-Drug Breakdown

The table below covers the most commonly used immunotherapy drugs in India, with per-cycle costs and approximate annual treatment costs. All figures are in USD.

Drug (Brand Name)	Mechanism	Dosing Frequency	India Cost per Cycle (USD)	USA Cost per Cycle (USD)	India Annual Cost (USD)
Pembrolizumab (Keytruda)	PD-1 inhibitor	Every 3 weeks	$1,500–$3,500	$10,000–$15,000	$26,000–$60,000
Nivolumab (Opdivo)	PD-1 inhibitor	Every 2–4 weeks	$1,200–$3,000	$9,000–$14,000	$22,000–$52,000
Atezolizumab (Tecentriq)	PD-L1 inhibitor	Every 3–4 weeks	$1,000–$2,500	$8,000–$13,000	$18,000–$43,000
Durvalumab (Imfinzi)	PD-L1 inhibitor	Every 4 weeks	$1,200–$2,800	$9,000–$14,000	$14,000–$34,000
Ipilimumab (Yervoy)	CTLA-4 inhibitor	Every 3 weeks (induction)	$2,500–$5,000	$20,000–$35,000	$40,000–$80,000 (induction phase)
Nivolumab + Ipilimumab (combination)	PD-1 + CTLA-4	Every 3 weeks	$3,500–$7,000	$25,000–$45,000	$60,000–$120,000 (induction)
Trastuzumab (Herceptin) — HER2 targeted	HER2 antibody	Every 3 weeks	$400–$900 (biosimilar)	$3,500–$8,000	$7,000–$15,000
Bevacizumab (Avastin) — anti-angiogenic	VEGF antibody	Every 2–3 weeks	$200–$600 (biosimilar)	$3,000–$8,000	$4,000–$10,000

 

Note: Annual cost figures assume continuous treatment for 12 months. Many immunotherapy protocols are time-limited (e.g. 2 years maximum for pembrolizumab in some indications) or are stopped earlier if disease progresses or if immune-related adverse events occur. Your oncologist will determine your treatment duration based on response.

Why Immunotherapy Is Cheaper in India — and What That Does and Does Not Mean

Immunotherapy drugs are patented biologics manufactured by pharmaceutical companies in the US, Europe, and increasingly Asia. In Western markets, pricing reflects research and development costs, regulatory approval costs, and market pricing power. In India, several factors reduce the cost significantly:

• Hospital procurement pricing: Indian hospitals negotiate lower drug procurement prices than individual patients buying retail. The per-cycle costs in the table above reflect hospital procurement rates, not retail pharmacy prices.
• Biosimilar availability: For monoclonal antibodies like trastuzumab and bevacizumab, Indian manufacturers have produced biosimilar versions — drugs that are clinically equivalent to the originator but manufactured off-patent. These cost 70–90% less than the originator brand. Checkpoint inhibitors (pembrolizumab, nivolumab) do not yet have approved Indian biosimilars; these are still originator products, but procured at lower Indian market rates.
• Lower hospital operating costs: Administration fees, nursing costs, and day-care facility costs for chemotherapy and immunotherapy sessions are lower in India than in Western hospitals, reducing the total per-cycle cost beyond just the drug price.
• Government import pricing controls: India’s drug pricing environment includes price caps on certain essential medicines, which constrains the ceiling price of some biologics.

 

What this does not mean: the drug itself is not different. Pembrolizumab administered in Mumbai is the same molecule as pembrolizumab administered in London. The clinical protocols — dosing, monitoring, management of immune-related adverse events — are the same at accredited Indian oncology centres as anywhere else. The cost difference is structural, not clinical.

 

Immunotherapy Cost by Cancer Type: What to Budget

The drug and its cost per cycle are only part of the picture. Total immunotherapy cost depends on which cancer you have, which drug or combination your oncologist recommends, how many cycles are prescribed, and whether immunotherapy is combined with chemotherapy or targeted therapy. Here is a cancer-type guide:

Cancer Type	Common Immunotherapy Protocol	Estimated Total Cost in India (USD)
Non-Small Cell Lung Cancer (PD-L1 high)	Pembrolizumab monotherapy, every 3 weeks, up to 2 years	$39,000–$90,000 total (2 years); most patients do not complete 2 years due to progression or toxicity
NSCLC (chemo + immunotherapy)	4–6 cycles carboplatin + pemetrexed + pembrolizumab, then pembrolizumab maintenance	$18,000–$45,000 for induction; maintenance adds $1,500–$3,500 per cycle ongoing
Melanoma (advanced)	Nivolumab + ipilimumab (4 combination cycles) then nivolumab maintenance	$28,000–$60,000 for induction phase; nivolumab maintenance ongoing
Head & Neck Cancer (recurrent / metastatic)	Pembrolizumab monotherapy or with chemotherapy	$18,000–$45,000 per year depending on regimen
Renal Cell Carcinoma	Nivolumab + ipilimumab or nivolumab + cabozantinib	$30,000–$70,000 per year for combination regimens
Gastric / Oesophageal Cancer	Nivolumab or pembrolizumab with chemotherapy	$15,000–$35,000 for induction + chemotherapy cycles
Hepatocellular Carcinoma (Liver Cancer)	Atezolizumab + bevacizumab (Tecentriq + Avastin)	$14,000–$28,000 per year (both drugs on biosimilar where available)
Breast Cancer (triple negative, advanced)	Pembrolizumab + chemotherapy	$20,000–$45,000 per year depending on chemo regimen and duration

Key Questions to Ask Before Starting Immunotherapy in India

• Has my tumour been tested for PD-L1 expression? — PD-L1 expression level determines whether pembrolizumab or nivolumab is indicated as monotherapy, in combination, or not at all. This test must be done on a tissue biopsy sample and is essential before immunotherapy is prescribed.
• Is MSI-H / MMR-deficient status relevant to my cancer? — Microsatellite instability-high tumours across multiple cancer types respond well to pembrolizumab regardless of cancer site. If MSI-H testing has not been done, ask your oncologist whether it is indicated.
• Which drug will be used, and is it the originator or a biosimilar? — For checkpoint inhibitors, only originator products are currently available in India. For trastuzumab and bevacizumab, biosimilars are available. Ask which version your treatment uses and what the cost difference is.
• How many cycles are planned, and under what conditions will treatment be stopped? — Immunotherapy is not always time-limited; some protocols continue until progression or toxicity. Understanding the stopping criteria helps you plan the financial commitment.
• What are the immune-related adverse event (irAE) monitoring protocols? — Checkpoint inhibitors can cause immune-related inflammation in any organ system. Management of serious irAEs may require hospitalisation, high-dose steroids, or treatment interruption. Ask how the hospital monitors for and manages these events.
• Can treatment be continued remotely or must I remain in India? — For patients who cannot stay in India for the full treatment duration, ask whether a treatment plan can be designed that includes cycles in India and continuation with the same drug in your home country.

What Is Not Included in Immunotherapy Cycle Costs

The per-cycle costs in this guide cover the drug and its administration. The following are typically billed separately and should be factored into your total treatment budget:

• Pre-treatment molecular testing: PD-L1 expression testing, MSI/MMR testing, and NGS panels — $200–$1,200 depending on tests required
• Imaging to assess treatment response: CT scan or PET-CT every 2–3 cycles — $400–$900 per scan
• Consultation fees for oncologist review prior to each cycle
• Management of immune-related adverse events: If a serious irAE occurs requiring hospitalisation, steroid treatment, or specialist input (gastroenterology, endocrinology, pulmonology), these costs are additional
• Combination chemotherapy drugs if immunotherapy is given alongside chemotherapy
• Supportive medications: anti-emetics, growth factors, and prophylactic antibiotics where indicated

 

Get a Personalised Immunotherapy Cost Estimate for India Immunotherapy cost depends on which drug your oncologist recommends, how many cycles are indicated, and whether your tumour’s molecular profile makes you eligible for monotherapy or combination treatment. A general range is a starting point; a case-specific estimate requires a specialist’s review of your biopsy and pathology reports. Share your pathology and molecular testing reports with our team. A matched oncologist will review your case and provide a written treatment plan — including the specific immunotherapy protocol recommended and an itemised cost estimate — at no charge. Free. Confidential. Reports reviewed within 24–48 hours.  |  www.racurehealthcare.com